All good, my friend. I personally think Joe did a pretty detailed view on the process and happenstances out of their control before IND approval. So if you read any press release relating to the work prior to the IND, and subsequently listen to the hours long CEO conference calls, you can put it all together to gain good understanding.

However, I DEFINITELY agree that July ending with a press release about Excellagen in locked down Malaysia is lame. The conference call set up news not for August, but by July 1. And that’s after a full year of talking about an IND. IND approval isn’t usually some awesome achievement. It’s just the start and Phase 3 success is the goal. Not success in mice, not in anything Generex has accomplished, but true Phase III human testing.

Personally, I don’t want to hear about a “complete vaccine” if it’s only a trademark. I don’t want to hear Generex saying current vaccines are unsafe, ineffective or anything. Get up to the plate and swing in the game already to talk. Put up or shut up.

We’ve all lost too much money. Stop pointing at goal marks that usually don’t take a year. Be better. Let’s go already. .235 should be an embarrassment, unacceptable. Especially considering current management started with an extreme reverse stock split.

Let’s get this IND behind us, actually start human trials, actually get NGIO spun out in an IPO, end loser money raises at stock suffering prices, and be winners. Hey, I had a traumatic brain injury a week ago, life is short, we understand difficulties, but let’s go already.